Alpine Immune Sciences Inc., a biotech company based in Seattle, has raised $150 million through underwritten public funding. According to Alpine, the new funding brings the company’s total cash to $227.2 million.
“Based on the strength of that and deep investor interest, we went out and decided to do a public offering,” said Mitchell Gold, co-founder and CEO of Alpine.
Alpine decided to facilitate a public offering due to “strong clinical data” amid its current clinical trials with ALPN-303, a drug intended to treat autoimmune and inflammatory disease, and ALPN-101, a drug beingtested for its performance in treating lupus.